vildagliptin/metformin sandoz 50 mg/850 mg
sandoz pharmaceuticals d.d., slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
dermitopic 1 mg/g masť
bausch health ireland limited, Írsko - takrolimus - 46 - dermatologica
vildagliptin/metformin stada 50 mg/1000 mg filmom obalené tablety
stada arzneimittel ag, nemecko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
vildagliptin/metformin stada 50 mg/850 mg filmom obalené tablety
stada arzneimittel ag, nemecko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
vimetso 50 mg/1000 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
vimetso 50 mg/850 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
tutecvi combi 50 mg/850 mg
viatris limited, Írsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
tutecvi combi 50 mg/1000 mg
viatris limited, Írsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
galvus
novartis europharm limited - vildagliptín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
jalra
novartis europharm limited - vildagliptín - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).